Evolocumab will lead acrocallosal syndrome therapeutics sales through 2036 with 41.3% of the category segment in 2026. Non-ST elevation myocardial infarction leads with a 37.6% share. The market was valued at USD 181.5 million in 2025, reaching USD 200.4 million by 2026-end and USD 538.9 million by 2036.